

# Umberto Manera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7179184/publications.pdf>

Version: 2024-02-01

67  
papers

2,683  
citations

279798

23  
h-index

214800

47  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3754  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	8.1	517
2	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	21.4	223
3	Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine. <i>JAMA Neurology</i> , 2014, 71, 1134.	9.0	150
4	The multistep hypothesis of ALS revisited. <i>Neurology</i> , 2018, 91, e635-e642.	1.1	146
5	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	5.3	118
6	Cognitive impairment across ALS clinical stages in a population-based cohort. <i>Neurology</i> , 2019, 93, e984-e994.	1.1	115
7	Genetic counselling in ALS: facts, uncertainties and clinical suggestions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 478-485.	1.9	99
8	ALS phenotype is influenced by age, sex, and genetics. <i>Neurology</i> , 2020, 94, e802-e810.	1.1	99
9	Rapamycin treatment for amyotrophic lateral sclerosis. <i>Medicine (United States)</i> , 2018, 97, e11119.	1.0	96
10	Secular Trends of Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 1097.	9.0	85
11	Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 666-673.	1.9	73
12	Psychological Treatments and Psychotherapies in the Neurorehabilitation of Pain: Evidences and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. <i>Frontiers in Psychology</i> , 2016, 7, 115.	2.1	66
13	Genetic architecture of ALS in Sardinia. <i>Neurobiology of Aging</i> , 2014, 35, 2882.e7-2882.e12.	3.1	60
14	UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. <i>Neurobiology of Aging</i> , 2013, 34, 357.e1-357.e5.	3.1	59
15	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1236.	9.0	46
16	Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 797-803.	1.9	45
17	CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. <i>Neurobiology of Aging</i> , 2015, 36, 1767.e3-1767.e6.	3.1	44
18	Psychological Considerations in the Assessment and Treatment of Pain in Neurorehabilitation and Psychological Factors Predictive of Therapeutic Response: Evidence and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. <i>Frontiers in Psychology</i> , 2016, 7, 468.	2.1	43

#	ARTICLE	IF	CITATIONS
19	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. <i>Neurobiology of Aging</i> , 2016, 43, 180.e1-180.e5.	3.1	40
20	What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications From the Italian Consensus Conference on Pain in Neurorehabilitation. <i>Frontiers in Neurology</i> , 2018, 9, 310.	2.4	40
21	Influence of cigarette smoking on ALS outcome: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1229-1233.	1.9	37
22	Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 590-597.	1.7	27
23	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 308-311.	1.7	27
24	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 11-19.	1.9	26
25	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. <i>Journal of Neurology</i> , 2019, 266, 1633-1642.	3.6	25
26	Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP43 subcellular distribution. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 133-153.	3.2	23
27	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. <i>Neurology</i> , 2021, 96, e600-e609.	1.1	23
28	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. <i>Neurobiology of Aging</i> , 2015, 36, 2906.e1-2906.e5.	3.1	19
29	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 291-297.	1.9	18
30	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1615-1621.	3.6	18
31	Validation of the revised classification of cognitive and behavioural impairment in ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 734-739.	1.9	17
32	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 Mutation. <i>Neurology</i> , 2021, 96, e141-e152.	1.1	17
33	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. <i>Neurobiology of Aging</i> , 2021, 98, 205-213.	3.1	15
34	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 146-148.	1.7	15
35	Metabolic brain changes across different levels of cognitive impairment in ALS: a <sup>18</sup> F-FDG-PET study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 357-363.	1.9	14
36	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectiology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2016, 52, 841-854.	2.2	14

#	ARTICLE	IF	CITATIONS
37	The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 999-1000.	1.9	13
38	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. <i>Brain</i> , 2021, 144, 3710-3726.	7.6	13
39	Brain metabolic changes across Kingâ€™s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1124-1133.	6.4	10
40	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€™FDGâ€™positron emission tomography stud. <i>European Journal of Neurology</i> , 2021, 28, 745-753.	3.3	10
41	Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a populationâ€™based cluster analysis. <i>European Journal of Neurology</i> , 2018, 25, 756-761.	3.3	9
42	Validation of the Italian version of self-administered ALSFRS-R scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 151-153.	1.7	9
43	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2242-2250.	6.4	9
44	Correlation between <i>Apolipoprotein E</i> genotype and brain metabolism in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 306-312.	3.3	8
45	The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. <i>Brain Sciences</i> , 2020, 10, 650.	2.3	8
46	What is amyotrophic lateral sclerosis prevalence?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 203-208.	1.7	8
47	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 33-39.	1.7	8
48	Social cognition deficits in amyotrophic lateral sclerosis: A pilot crossâ€™sectional populationâ€™based study. <i>European Journal of Neurology</i> , 2022, 29, 2211-2219.	3.3	8
49	NADPH oxidases 2 activation in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 110-111.	2.2	7
50	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. <i>NeuroImage: Clinical</i> , 2020, 27, 102312.	2.7	7
51	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 103, 130.e1-130.e7.	3.1	7
52	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2022, 12, 395.	3.3	7
53	A novel p.E121G heterozygous missense mutation of SOD1 in an apparently sporadic ALS case with a 14-year course. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 127-128.	1.7	6
54	ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion. <i>Neurobiology of Aging</i> , 2016, 39, 218.e5-218.e8.	3.1	6

#	ARTICLE	IF	CITATIONS
55	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 1181-1187.	3.3	4
56	Brain <sup>18F</sup> fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with <i>TARDBP</i> mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1021-1023.	1.9	4
57	Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 274-276.	1.7	3
58	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 223-225.	1.5	3
59	GBA variants influence cognitive status in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, , jnnp-2021-327426.	1.9	3
60	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 216, 106681.	4.7	3
61	Alcohol Consumption and the Risk of Amyotrophic Lateral Sclerosis. , 2019, , 207-216.		2
62	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-9.	1.7	2
63	Correlations between measures of ALS respiratory function: is there an alternative to FVC?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 495-504.	1.7	2
64	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 424-429.	1.7	2
65	Tailoring patients' enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 108-115.	1.7	1
66	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-7.	1.7	1
67	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. <i>European Neurology</i> , 2020, 83, 626-629.	1.4	1